These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 17383596)
1. Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Mizuochi Y; Okajima K; Harada N; Molor-Erdene P; Uchiba M; Komura H; Tsuda T; Katsuya H Transl Res; 2007 Apr; 149(4):223-30. PubMed ID: 17383596 [TBL] [Abstract][Full Text] [Related]
2. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Arai M; Uchiba M; Komura H; Mizuochi Y; Harada N; Okajima K J Pharmacol Exp Ther; 2010 Jul; 334(1):206-13. PubMed ID: 20371705 [TBL] [Abstract][Full Text] [Related]
3. Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Chen JW; Lin FY; Chen YH; Wu TC; Chen YL; Lin SJ Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2075-81. PubMed ID: 15374848 [TBL] [Abstract][Full Text] [Related]
4. Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats. Okajima K; Harada N; Uchiba M; Isobe H J Pharmacol Exp Ther; 2004 May; 309(2):684-91. PubMed ID: 14764656 [TBL] [Abstract][Full Text] [Related]
5. Antithrombin inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by monocytes in vitro through inhibition of Egr-1 expression. Komura H; Uchiba M; Mizuochi Y; Arai M; Harada N; Katsuya H; Okajima K J Thromb Haemost; 2008 Mar; 6(3):499-507. PubMed ID: 18088351 [TBL] [Abstract][Full Text] [Related]
6. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. Yuksel M; Okajima K; Uchiba M; Okabe H J Pharmacol Exp Ther; 2003 Apr; 305(1):298-305. PubMed ID: 12649382 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic profile of carvedilol. van Zwieten PA Cardiology; 1993; 82 Suppl 3():19-23. PubMed ID: 8106159 [TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Nichols AJ; Gellai M; Ruffolo RR Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335 [TBL] [Abstract][Full Text] [Related]
9. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Ohsawa M; Koyama T; Nara N; Hirosawa S Thromb Res; 2003; 112(5-6):313-20. PubMed ID: 15041276 [TBL] [Abstract][Full Text] [Related]
10. Sp1 is an essential transcription factor for LPS-induced tissue factor expression in THP-1 monocytic cells, and nobiletin represses the expression through inhibition of NF-kappaB, AP-1, and Sp1 activation. Hirata Y; Masuda Y; Kakutani H; Higuchi T; Takada K; Ito A; Nakagawa Y; Ishii H Biochem Pharmacol; 2008 Apr; 75(7):1504-14. PubMed ID: 18261712 [TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575 [TBL] [Abstract][Full Text] [Related]
12. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. Martin L; Pingle SC; Hallam DM; Rybak LP; Ramkumar V J Pharmacol Exp Ther; 2006 Jan; 316(1):71-8. PubMed ID: 16188954 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of lipopolysaccharide-induced tissue factor expression in monocytes by urinary trypsin inhibitor in vitro and in vivo. Molor-Erdene P; Okajima K; Isobe H; Uchiba M; Harada N; Shimozawa N; Okabe H Thromb Haemost; 2005 Jul; 94(1):136-45. PubMed ID: 16113797 [TBL] [Abstract][Full Text] [Related]
14. The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species. Lin PY; Shen HC; Chen CJ; Wu SE; Kao HL; Huang JH; Wang DL; Chen SC J Thromb Thrombolysis; 2010 Jan; 29(1):52-9. PubMed ID: 19333555 [TBL] [Abstract][Full Text] [Related]
15. Carvedilol and adrenergic agonists suppress the lipopolysaccharide-induced NO production in RAW 264.7 macrophages via the adrenergic receptors. Pekarova M; Kralova J; Kubala L; Ciz M; Papezikova I; Macickova T; Pecivova J; Nosal R; Lojek A J Physiol Pharmacol; 2009 Mar; 60(1):143-50. PubMed ID: 19439816 [TBL] [Abstract][Full Text] [Related]
16. BMP-2 inhibits TF expression in human monocytes by shutting down MAPK signaling and AP-1 transcriptional activity. Egorina EM; Sovershaev TA; Hansen JB; Sovershaev MA Thromb Res; 2012 Apr; 129(4):e106-11. PubMed ID: 22119392 [TBL] [Abstract][Full Text] [Related]
17. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Song G; Hennessy M; Zhao YL; Li Q; Han WD; Qi Y; Zhao WN; Silke B; Barry M; Doyle R; Spiers JP Pharmacol Res; 2006 Jul; 54(1):57-64. PubMed ID: 16574429 [TBL] [Abstract][Full Text] [Related]
18. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. Qvigstad E; Sjaastad I; Bøkenes J; Schiander I; Solberg L; Sejersted OM; Osnes JB; Skomedal T Eur J Pharmacol; 2005 May; 516(1):51-9. PubMed ID: 15916756 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of lipopolysaccharide-stimulated NO production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages involving the blockade of MEK4/JNK/AP-1 pathway. Lin MW; Tsao LT; Chang LC; Chen YL; Huang LJ; Kuo SC; Tzeng CC; Lee MR; Wang JP Biochem Pharmacol; 2007 Jun; 73(11):1796-806. PubMed ID: 17379190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]